REGULATORY

Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting

July 13, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The cost-effective assessment (CEA) subcommittee of the Central Social Insurance Medical Council, better known as Chuikyo, on July 12 launched discussions on an interim report due out this summer on the full introduction of a “CEA” scheme in April next…

To read the full story

MHLW Presents Draft Survey Sheet for “Willing-to-Pay” Costs in “CEA” Scheme: Chuikyo
July 13, 2017

REGULATORY

10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…